secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001104659-25-018275
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics: aleniglipron studies fully enrolled; Q4 net loss $36.5M, cash $883.5M
--------------------------------------------------------------------------------

- ACCESS and ACCESS II studies fully enrolled on schedule; topline 36-week data expected by year-end 2025.
- Cash, cash equivalents and short-term investments $883.5M as of Dec 31, 2024; expected to fund operations through 2027.
- Net loss Q4 2024 $36.5M ($24.5M Q4 2023); FY2024 net loss $122.5M ($89.6M FY2023).
- Oral amylin agonist ACCG-2671: IND-enabling activities underway; Phase 1 initiation expected by year-end 2025.
- R&D expenses increased to $33.5M for Q4 2024 from $20.0M; full year $108.8M from $70.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465925018275/0001104659-25-018275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465925018275/tm257591d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-018275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer